Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 1/20 | 0.46 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | ALPL | P05186 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2083640 | 0.79 | CXCR4 (0.52) | CXCR4DDAH1RAB9AKDM4EPIN1 | |
| SCHEMBL8025715 | 0.69 | DDAH1 (0.61) | DDAH1RAB9AKDM4ENPC1POLB | |
| SCHEMBL15908506 | 0.69 | KCNA5 (0.47) | SMN1; SMN2MAPK1 | |
| SCHEMBL30207649 | 0.69 | DDAH1 (0.61) | DDAH1RAB9AKDM4ENPC1POLB | |
| SCHEMBL825212 | 0.68 | RAB9A (0.57) | DDAH1RAB9AKDM4ENPC1LMNA | |
| SCHEMBL11479351 | 0.68 | KDM4E (0.46) | DDAH1RAB9AKDM4EPIN1LMNA | |
| SCHEMBL5112746 | 0.67 | CXCR4 (0.52) | CXCR4SLC40A1 | |
| SCHEMBL30834051 | 0.67 | CXCR4 (0.52) | CXCR4SLC40A1 | |
| SCHEMBL5103871 | 0.67 | CXCR4 (0.52) | CXCR4SLC40A1 | |
| SCHEMBL4759592 | 0.67 | CXCR4 (0.52) | CXCR4SLC40A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7863293-B2 | CXCR4 chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2011-01-04 | — | — | US | claimed |
| US-20080255197-A1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED CORPORATION (CA) | 2008-10-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255197-A1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | CXCR4, CXCR1, CXCR3 | CXCR4 1/4885DDAH1 4193/4885RAB9A 983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.